Adjuvant dendritic cell-based immunotherapy in melanoma: insights into immune cell dynamics and clinical evidence from a phase II trial

被引：0

作者：

Jenny Bulgarelli ^{[1
]}

Claudia Piccinini ^{[1
]}

Emanuela Scarpi ^{[2
]}

Giorgia Gentili ^{[2
]}

Laura Renzi ^{[3
]}

Silvia Carloni ^{[1
]}

Francesco Limarzi ^{[4
]}

Elena Pancisi ^{[1
]}

Anna Maria Granato ^{[1
]}

Massimiliano Petrini ^{[1
]}

Francesco De Rosa ^{[1
]}

Massimo Guidoboni ^{[5
]}

Dalila Fanelli ^{[1
]}

Maria Maddalena Tumedei ^{[1
]}

Marcella Tazzari ^{[1
]}

Stefano Baravelli ^{[6
]}

Ilaria Bronico ^{[7
]}

Pietro Cortesi ^{[8
]}

Sara Pignatta ^{[1
]}

Laura Capelli ^{[9
]}

Valentina Ancarani ^{[1
]}

Giovanni Foschi ^{[1
]}

Livia Turci ^{[1
]}

Francesca Tauceri ^{[10
]}

Massimo Framarini ^{[10
]}

Laura Ridolfi ^{[1
]}

机构：

[1] Advanced Cellular Therapies and Rare Tumors Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola

[2] Unit of Biostatistics and Clinical Trials, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola

[3] Medical Genetics Unit, AUSL Romagna, Cesena

[4] Pathology Unit, Morgagni-Pierantoni Hospital, AUSL Romagna, Forlì

[5] Department of Oncology, University Hospital of Ferrara, Ferrara

[6] Unit of Immunohematology and Transfusion Medicine, Morgagni-Pierantoni Hospital, AUSL Romagna, Forlì

[7] Radiotherapy Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola

[8] Cardio-Oncology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola

[9] Bioscience Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” (IRST), Meldola

[10] Advanced Oncological Surgery Unit, Morgagni-Pierantoni Hospital, AUSL Romagna, Forlì

来源：

Journal of Translational Medicine | / 23卷 / 1期

关键词：

Dendritic cell; Immune modulatory; Immunotherapy; Skin cancer; Tumor microenvironment;

D O I：

10.1186/s12967-025-06403-8

中图分类号：

学科分类号：

摘要：

Background: Dendritic cells (DCs) are the most efficient antigen-presenting cells and play a central role in the immune system, orchestrating immune response against tumors. We previously demonstrated that DC-based vaccination effectively induces anti-tumor immunity, yet at the same time showing a robust safety profile, making this treatment a potential candidate for effective adjuvant immunotherapy. To explore this possibility, we designed a randomized phase II trial (EudraCT no. 2014-005123-27) to provide a complementary autologous DC vaccination to patients (pts) with resected stage III/IV melanoma. Methods: Overall, a total of 18 eligible pts were included in this study, 10 of whom received 6 monthly DC vaccination cycles combined with IL-2 administration (arm A), and 8 pts were enrolled in the follow-up observational cohort (arm B). A deep immune biomarkers profiling by multiplex immunoassay, human leukocyte antigens (HLA) typing, multiparametric flow cytometry and in situ tumor microenvironment analysis was performed for the entire pts cohort. The immunological response was assessed in vivo by DTH test and ex vivo against selected melanoma-associated antigens applying the IFN-γ ELISPOT assay. Results: Pts receiving DC vaccination showed a better relapse-free survival compared to the observational cohort (median 6.6 months, 95% CI, 2.3–not reached (nr) (arm A) vs 5.2 months, 95% CI, 2.5–nr (arm B), not significant), with a favorable trends for female pts (median 15.5 months, 95% CI, 2.6–nr (female) vs 3.3, 95% CI, 2.3–nr (male)), pts with less than 60 years (median 22.5 months, 95% CI, 2.6–nr (age < 60) vs 4.7 months, 95% CI, 2.3–nr (age ≥ 60), and pts with wild-type BRAF status (median 22.5 months, 95% CI, 8.6–nr (BRAF wt) vs 3.8 months, 95% CI, 2.3–nr (BRAF mutated). The toxicity profile was favourable, with no severe adverse events and only mild, manageable reactions. Moreover, additional immune response data suggested increased immune modulation in vaccinated patients, which may reflect a shift in immune dynamics. Conclusions: Our findings support the safety and tolerability of DC vaccination as an adjuvant treatment for melanoma, demonstrating significant immune modulation at both the tumor site and peripherally in relapsed and non-relapsed patients. These results highlight the potential of autologous, personalised DC-based therapies and pave the way for the development of innovative immunotherapy combinations in future treatment strategies. Trial registration ClinicalTrials.gov NCT02718391; EudraCT no. 2014-005123-27. © The Author(s) 2025.

引用

共 47 条

[1] Mocellin S., Pasquali S., Rossi C.R., Nitti D., Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis, J Natl Cancer Inst, 102, 7, pp. 493-501, (2010)
[2] Eggermont A.M.M., Chiarion-Sileni V., Grob J.-J., Et al., Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial, Lancet Oncol, 16, 5, pp. 522-530, (2015)
[3] Eggermont A.M.M., Chiarion-Sileni V., Grob J.-J., Et al., Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy, N Engl J Med, 375, 19, pp. 1845-1855, (2016)
[4] Larkin J., Del Vecchio M., Mandala M., Et al., Adjuvant nivolumab versus ipilimumab in resected stage III/IV melanoma: 5-year efficacy and biomarker results from CheckMate 238, Clin Cancer Res, 29, 17, pp. 3352-3361, (2023)
[5] Long G.V., Hauschild A., Santinami M., Et al., Final results for adjuvant dabrafenib plus trametinib in stage III melanoma, N Engl J Med, 391, 18, pp. 1709-1720, (2024)
[6] Eggermont A.M., Kicinski M., Blank C.U., Et al., Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial, Eur J Cancer, 211, (2024)
[7] Livingstone E., Zimmer L., Hassel J.C., Fluck M., Eigentler T.K., Loquai C., Et al., Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial, Lancet, 400, pp. 1117-1129, (2022)
[8] Najafi S., Mortezaee K., Advances in dendritic cell vaccination therapy of cancer, Biomed Pharmacother, 164, (2023)
[9] Rodriguez J., Castanon E., Perez-Gracia J.L., Et al., A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis, J Immunother Cancer, 6, 1, (2018)
[10] Nava S., Lisini D., Frigerio S., Bersano A., Dendritic cells and cancer immunotherapy: the adjuvant effect, Int J Mol Sci, 22, 22, (2021)

← 1 2 3 4 5 →